B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy

Heart

Volumn 94, Issue 10, 2008, Pages 1307-1311

  Kaski, J P ^a   Esteban, M T Tomé ^a   Mead Regan, S ^a   Pantazis, A ^a   Marek, J ^a   Deanfield, J E ^a   McKenna, W J ^a   Elliott, P M ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; DEFIBRILLATOR; DISEASE MARKER; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE WALL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; MALE; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DIASTOLE; FEMALE; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 52649140490     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.126748     Document Type: Article

References (41)

1. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-91.
2. Harris KM, Spirito P. Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216-25.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
4. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
5. Ten Cate FJ, Roelandt J. Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J 1979;97:762-5.
6. Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005;91:920-5.
7. Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004;44:398-405.
8. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004;23:1313-33.
9. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
10. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
11. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
12. Richards AM, Crozier IG, Yandle TG, et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-7.
13. Isnard R, Pousset F, Trochu J, et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417-21.
14. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
15. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99:786-92.
16. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42.
17. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
18. Maron BJ, Tholakanahalli VN, Zenovich AG, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004;109:984-9.
19. Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 2000;86:1036-40, A11.
20. Okawa M, Kitaoka H, Matsumura Y, et al. Functional assessment by myocardial performance index (Tei index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy. Circ J 2005;69:951-7.
21. Thaman R, Esteban MT, Barnes S, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006;98:515-9.
22. Cowley CG, Bradley JD, Shaddy RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004;25:336- 40.
23. Hammerer-Lercher A, Geiger R, Mair J, et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem 2006;52:1415-9.
24. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-8.
25. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861- 6.
26. Koulouri S, Acherman RJ, Wong PC, et al. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004;25:341-6.
27. Law YM, Keller BB, Feingold BM, et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005;95:474-8.
28. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006;114:1063-9.
29. Soldin SJ, Soldin OP, Boyajian AJ, et al. Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals. Clin Chim Acta 2006;366:304-8.
30. Westerlind A, Wahlander H, Lindstedt G, et al. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004;93:340-5.
31. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93:841-2.
32. First T, Skovranek J, Marek J. [Normal values of 2-dimensional echocardiographic parameters in children]. Cesk Pediatr 1992;47:260-4.
33. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348:1639-46.
34. Matsumura Y, Elliott PM, Virdee MS, et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 2002;87:247-51.
35. Yetman AT, Hamilton RM, Benson LN, et al. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32:1943-50.
36. McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109:1756-62.
37. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9.
38. Arteaga E, Araujo AQ, Buck P, et al. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005; 150:1228-32.
39. Kapusta L, Thijssen JM, Cuypers MH, et al. Assessment of myocardial velocities in healthy children using tissue Doppler imaging. Ultrasound Med Biol 2000;26:229-37.
40. Mori K, Hayabuchi Y, Kuroda Y, et al. Left ventricular wall motion velocities in healthy children measured by pulsed wave Doppler tissue echocardiography: normal values and relation to age and heart rate. J Am Soc Echocardiogr 2000;13:1002-11.
41. Swaminathan S, Ferrer PL, Wolff GS, et al. Usefulness of tissue Doppler echocardiography for evaluating ventricular function in children without heart disease. Am J Cardiol 2003;91:570-4.